William Blair has acquired Armentum Partners, a boutique debt and alternative capital advisory firm serving venture-backed companies, public companies, academic institutions, and other organizations.
The transaction represents William Blair’s second investment banking acquisition of 2026 and expands the firm’s capabilities across debt advisory, enterprise value lending, asset-based lending, and royalty monetization.
Armentum Partners focuses primarily on the healthcare and technology sectors, advising high-growth companies on customized financing strategies. The firm maintains relationships with venture capital investors, public companies, growth-oriented lenders, and enterprise-value lenders.
Its royalty monetization practice also advises academic institutions and life sciences companies seeking to generate capital from intellectual property and royalty streams.
Armentum has raised more than $22 billion since its founding across more than 390 transactions. Its senior banking team has more than 200 years of combined experience spanning investment banking, commercial banking, lending, venture financing, private and public equity investing, and business development.
The firm has professionals in Boston, Chicago, Menlo Park, New York, Philadelphia, and San Francisco, and serves clients across the United States and Europe.
All Armentum professionals are expected to join William Blair as part of the transaction. William Blair will also open an office in Menlo Park, giving the firm a direct presence in Silicon Valley.
Armentum will continue operating under its existing name for a period following the transaction.
William Blair said the acquisition responds to increasing demand for private credit and other forms of non-dilutive financing among venture-backed and public companies. Growth has been particularly notable across healthcare innovation, artificial intelligence, software, consumer, media, fintech, and industrial technology.
The firm also sees increasing demand among later-stage technology businesses and biopharmaceutical companies seeking financing for clinical development, commercialization, acquisitions, and other growth initiatives.
The acquisition follows William Blair’s recent expansion in life sciences, including the additions of Michael Allwin as Head of Biopharma Investment Banking, Emanuela Branchetti as Managing Director of Scientific Affairs, and Alethia Young in equity research.
William Blair’s investment banking group advised on more than $880 billion in completed transaction volume from July 2021 through June 2026.
Support: Clearsight Advisors served as financial advisor to Armentum Partners on the transaction.
KEY QUOTES:
“We continue to invest in capabilities and teammates who can provide differentiated outcomes for our clients across the venture capital, public company, and collegiate communities. The Armentum Partners team has decades of experience earning the trust of their clients, key investors and lenders in their markets, and the institutions and universities that fuel innovation. Together, we can offer these clients a broader set of solutions to finance their continued growth.”
Matt Zimmer, Global Head Of Investment Banking At William Blair
“This is a natural synergistic extension of our capital markets strategy. Enterprise value lending is a specialized discipline—financing companies against the value of their assets, often before traditional cash flows exist. Armentum Partners has built a leading franchise advising many of the most well-known and innovative public companies, universities and venture-backed businesses.”
Steve Maletzky, Head Of Capital Markets At William Blair
“We built our firm with a dedicated focus on our clients, offering them access to our deep market relationships and expertise in delivering bespoke solutions. Joining William Blair unlocks opportunities for our clients, providing the increased scale, reach, and sector depth of a premier global platform along with relationship and execution continuity. We can now offer our clients a much deeper set of services—including public and private equity capital raising, M&A advisory, secondary advisory, primary fundraising, and equity research—while leveraging William Blair’s sector breadth to cover adjacent industries.”
Hutch Corbett, Armentum Partners
